Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tdon1229on Jan 23, 2022 10:29pm
607 Views
Post# 34350834

RE:90 Day Period & 180 Day Period

RE:90 Day Period & 180 Day Period
99942Apophis wrote: Newsletter dated November 29 had patients 25 to 30 being treated from the previous Newsletter dated August 30/2021 a time-frame of 3 months. A reasonable assumption would be 2 patients treated per month. 
We are now approaching the end of January/2022 which of course is 2 months since the last Newsletter or 4 of the 6 ( patients 25, 26, 27 & 28 ) that were announced treated should have hit that 90 point. 
The 90 day end point I believe is plus or minus 7 days! 

Looking at the 180 Day we had in the Newsletter of August 30/2021 patients 21 to 24 treated from the previous Newsletter dated June11/2021. That gives us 2 months 3 weeks, lets just say 1 patient for June and 1 for July  with 2 for August. That would now put patients 21 & 22 hitting their 180 point at the end of January/2022. 
 
End of February to first week of March in my opinion is Newsletter territory, however news of material substance could be released at any time. 



Can't see them being allowed to count any of the first 12 patients treated because of the gross under treatments they received.  The only ones they can count are those correctly treated twice as specified for the clinical trial.  All others are merely talking points and additional information, not properly treated Phase II trial subjects.  Same for the information about the long term results for the two surviving Phase I trial subjects, nice to know, but don't count formally for anything in Phase II.
i awouldn't hold my breath expecting a BTD submittal until they have 20-25 legitimate Ph II trial subject results for 90 & 180 days.

<< Previous
Bullboard Posts
Next >>